描述 2017 年亚洲各地诊断为视网膜母细胞瘤 (RB) 的儿童的临床表现和治疗结果。这项跨国前瞻性研究包括 2017 年亚洲诊断为视网膜母细胞瘤的初治患者及其后的随访。总计 2112 例来自 33 个亚洲国家 96 个 RB 治疗中心的患者（2797 只眼睛）。化疗、放疗、摘除术、眼眶摘除术 主要观察指标：摘除术和死亡 结果：队列中 1021 名 (48%) 患者来自南亚 (SA)、 503 名（24%）来自东亚（EA），310 名（15%）来自东南亚（SEA），218 名（10%）来自西亚（WA），60 名（3%）来自中亚（CA）。就诊时的平均年龄为 27 个月（中位年龄 23 个月；范围 <1 至 261 个月）。其中男性 1195 名（57%），女性 917 名（43%）。最常见的主诉是白瞳症（72%）和斜视（13%）。根据第 8 版美国癌症联合委员会的数据，肿瘤分期为 cT1（n=441；16%）、cT2（n=951；34%）、cT3（n=1136；41%）、cT4（n=267；16%）。 10%）、N1（n=48；2%）和 M1（n=129；6%）。 1450 只眼睛 (52%) 接受了 RB 静脉化疗，其中 857 只眼睛 (31%) 接受了初次摘除术。 Kaplan-Meier 对眼球摘除和死亡的三年估计分别为：CA 为 33% 和 13%，EA 为 18% 和 4%，SA 为 27% 和 15%，SEA 为 32% 和 22%，SEA 为 20% 和 11%。 WA（分别为p<0.0001和p<0.0001）。在本研究结论中，亚洲大陆各地区之间的RB治疗结果存在显着异质性。东亚的结果较好，全球和生命救助率较高，而与亚洲其他地区相比，东南亚的结果较差。版权所有 © 2023。由 Elsevier Inc. 出版。

To describe the clinical presentation and treatment outcomes of children diagnosed with retinoblastoma (RB) in the year 2017, throughout Asia.Multi-national prospective study including treatment-naïve patients diagnosed with retinoblastoma in Asia during 2017 and followed up thereafter.A total of 2112 patients (2797 eyes) from 96 RB treatment centers in 33 Asian countries.Chemotherapy, radiotherapy, enucleation, orbital exenteration MAIN OUTCOME MEASURES: Enucleation and death RESULTS: Within the cohort, 1021 (48%) patients were from South Asia (SA), 503 (24%) from East Asia (EA), 310 (15%) from South-East Asia (SEA), 218 (10%) from West Asia (WA) and 60 (3%) from Central Asia (CA). Mean age at presentation was 27 months (median, 23 months; range, <1 to 261 months). There were 1195 (57%) males and 917 (43%) females. The most common presenting complaints were leukocoria (72%) and strabismus (13%). Based on 8th edition American Joint Committee for Cancer, tumors were staged as cT1 (n=441; 16%), cT2 (n=951; 34%), cT3 (n=1136; 41%), cT4 (n=267; 10%), N1 (n=48; 2%), and M1 (n=129; 6%) at presentation. RB was treated with intravenous chemotherapy in 1450 (52%) eyes and 857 (31%) underwent primary enucleation. Three-year Kaplan-Meier estimates for enucleation and death were 33% and 13% for CA, 18% and 4% for EA, 27% and 15% for SA, 32% and 22% for SEA, 20% and 11% for WA (p<0.0001 and p<0.0001), respectively.At the conclusion of this study, there was a significant heterogeneity in treatment outcomes of RB between the regions of Asian continent. East Asia displayed better outcomes with higher rates of globe and life salvage, while South-East Asia had poorer outcomes compared to the rest of Asia.Copyright © 2023. Published by Elsevier Inc.